Filing Flows › Merck (MRK) › R&D spending
Merck (MRK) R&D spending by quarter
Merck's R&D spending was $4.5B in Q3 2026 (third quarter 2026), -53% from Q2 2026. Over the last 6 quarters it ranged from $3.6B (Q1 2025) to $12.6B (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.5B | -53% | — |
| Q2 2026 | $9.7B | -23% | +141% |
| Q1 2026 | $12.6B | +224% | +248% |
| Q4 2025 | $3.9B | -4% | — |
| Q2 2025 | $4.0B | +12% | — |
| Q1 2025 | $3.6B | — | — |
Q3 2026 at a glance
Merck, Q3 2026: revenue $18.1B (+5% year over year), operating margin 30.7%, net earnings $5.1B, operating cash flow $6.6B. The chart follows the revenue to costs, profit and cash.
Questions
What is Merck's R&D spending?
Merck's R&D spending was $4.5B in Q3 2026 (third quarter 2026), -53% from Q2 2026.
How has Merck's R&D spending changed?
Over the last 6 quarters it ranged from $3.6B (Q1 2025) to $12.6B (Q1 2026).